BA
AKBA icon

Bristol Advisors’s Akebia Therapeutics AKBA Stock Holding History

Bristol Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$157K Hold
19,128
– – 0.37% 20
2018
Q4 		$106K Buy
+19,128
New +$150K 0.13% 48

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Bristol Advisors's AKBA Position: Q1 2019 in Review

Bristol Advisors held its Akebia Therapeutics (AKBA) position steady in Q1 2019 at 19,128 shares worth $157K. The position accounts for 0.37% of the portfolio, ranked #20.

Bristol Advisors first reported a position in AKBA in Q4 2018 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold AKBA as of Q1 2019.

  • Bristol Advisors held 19,128 shares of Akebia Therapeutics worth $157K as of Q1 2019.
  • Bristol Advisors left its Akebia Therapeutics share count unchanged in Q1 2019.
  • Akebia Therapeutics made up 0.37% of Bristol Advisors's portfolio in Q1 2019, its #20 holding.
  • Bristol Advisors first reported a position in Akebia Therapeutics in Q4 2018 and has held it in 2 quarters since.
  • 169 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2019.

Based on Bristol Advisors's 13F filing for Q1 2019, filed 29 Apr 2019.